Dana-Farber/Harvard Cancer Center

Boston, Massachusetts 02215

7 studies enrolling now · 36 studies all time

What they study most

Accelerated Phase Chronic Myelogenous Leukemia, Adherence, Medication, Adolescent Behavior, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Rhabdomyosarcoma, Advanced Cancer, Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer

Studies at this site

• A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) — Recruiting now
• A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer — Recruiting now
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments — Recruiting now
• Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma — Recruiting now
• A Study of MGC028 in Participants With Advanced Solid Tumors — Recruiting now
• XL092 and Cemiplimab in BRAF WT Thyroid Cancer — Recruiting now
• SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma — Running, not enrolling
• A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) — Running, not enrolling
• Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study — Running, not enrolling
• Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma — Running, not enrolling
• Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment — Paused
• Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma — Running, not enrolling
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Running, not enrolling
• Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia — Running, not enrolling
• Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD — Stopped early
• The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation — Completed
• A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, — Stopped early
• Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma — Completed
• A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer — Completed
• An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer — Stopped early
• A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer — Completed
• A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma — Completed
• Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma — Completed
• Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 — Completed
• Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy — Completed
• Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors — Completed
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer — Completed
• Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma — Completed
• A Study of ARQ 171 in Patients With Advanced Solid Tumors — Stopped early
• Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer — Completed
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors — Completed
• Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer — Completed
• Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase — Completed
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer — Completed
• An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer — Completed